A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Conditions: Metastatic Esophageal Carcinoma; Advanced Unresectable Gastric Adenocarcinoma; Metastatic Gastric Cancer; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Esophageal Cancer; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastric Carcinoma; Unresectable Esophageal Cancer; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Carcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: AgenT-797; Biological: Botensilimab; Drug: Balstilimab; Drug: Ramucirumab; Drug: Paclitaxel

Sponsors: Memorial Sloan Kettering Cancer Center

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 10, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments